Group 1 - The core announcement is that Lianhuan Pharmaceutical's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for the drug named Meiasartan Potassium Tablets [2] Group 2 - The approval of the drug registration certificate indicates a significant regulatory milestone for the company, potentially enhancing its product portfolio and market presence [2] - The drug Meiasartan Potassium Tablets may contribute to the company's revenue growth and competitive positioning in the pharmaceutical industry [2]

Core Viewpoint - The company has received a drug registration certificate for Benazepril Potassium Tablets, which will enhance its product line and market competitiveness [1] Group 1: Company Developments - The company's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has been approved by the National Medical Products Administration for the registration of Benazepril Potassium Tablets [1] - The approved dosage forms are 40mg and 80mg, which are intended for the treatment of adult primary hypertension [1] - The acquisition of the drug registration certificate is expected to enrich the product line of the company and its subsidiaries [1] Group 2: Market Impact - The approval is anticipated to improve the market competitiveness of the company's products [1] - The company does not expect a significant impact on its recent operating performance from this approval [1]

Group 1 - The core point of the article is that Lianhuan Pharmaceutical (600513) announced the approval of its subsidiary Changle Pharmaceutical's drug, Benazepril Potassium Tablets, by the National Medical Products Administration, which can be used for the treatment of primary hypertension in adults [1] Group 2 - The drug Benazepril Potassium Tablets has received a drug registration certificate, indicating its compliance with regulatory standards [1] - This approval may enhance the company's product portfolio and market presence in the hypertension treatment segment [1] - The approval reflects the ongoing efforts of the company to expand its pharmaceutical offerings and address health issues related to hypertension [1]

Core Viewpoint - The company announced that its subsidiary, Changle Pharmaceutical, received approval from the National Medical Products Administration for the registration of Mezasartan Potassium Tablets (40mg/80mg), which are used to treat primary hypertension in adults [1] Group 1 - The research and development investment for Mezasartan Potassium Tablets amounted to approximately RMB 10.99 million [1] - As of the announcement date, Changle Pharmaceutical has obtained 10 production licenses for the product [1] - The approval of the drug registration certificate is not expected to have a significant impact on the company's recent operating performance [1]

Core Viewpoint - The company has received a drug registration certificate for its product, Amlodipine Besylate Tablets, which is expected to enhance its product line and market competitiveness [1]. Group 1: Product Development - The company's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has been granted a drug registration certificate by the National Medical Products Administration for Amlodipine Besylate Tablets [1]. - The product is indicated for the treatment of primary hypertension in adults, with projected sales of approximately 58.73 million yuan in 2024 [1]. - The registration application for Amlodipine Besylate Tablets (40mg/80mg) was first submitted in August 2024 and has now been approved, signifying compliance with the consistency evaluation of generic drug quality and efficacy [1]. Group 2: Financial Investment - The research and development investment for Amlodipine Besylate Tablets has reached approximately 10.99 million yuan (unaudited) as of the announcement date [1]. - The company has obtained 10 production licenses for the product as of the announcement date [1]. Group 3: Market Impact - The acquisition of the drug registration certificate is expected to enrich the company's product line and enhance the competitiveness of its products in the market [1]. - The impact of this registration on the company's recent operating performance is not anticipated to be significant [1].

Core Viewpoint - The announcement by Lianhuan Pharmaceutical regarding the approval of its subsidiary Changle Pharmaceutical's drug, Amlodipine Besylate Tablets, indicates progress in the company's product pipeline, although it is not expected to significantly impact recent financial performance [2] Group 1: Company Developments - Lianhuan Pharmaceutical's subsidiary, Changle Pharmaceutical, received the drug registration certificate for Amlodipine Besylate Tablets (40mg/80mg) from the National Medical Products Administration [2] - The research and development investment for Amlodipine Besylate Tablets amounted to approximately RMB 10.99 million [2] - As of the announcement date, Changle Pharmaceutical has obtained 10 production licenses for its products [2] Group 2: Market Impact - The approval of Amlodipine Besylate Tablets is intended for the treatment of primary hypertension in adults [2] - The company anticipates that this approval will not have a significant impact on its recent operating performance [2]

Core Viewpoint - The company emphasizes innovation in its research and development strategy, focusing on innovative drugs, improved new drugs, and generic drugs with technical barriers, while gradually reducing investment in ordinary generic drugs [1] Group 1: R&D Focus - The company has six ongoing innovative drug R&D projects, with the core project LH-1801 (SGLT-2 inhibitor) currently in the Ⅲ phase clinical trial, expected to unblind in Q1 2026 [1] - LH-1801 demonstrates differentiated advantages in controlling glycosylated hemoglobin and offers benefits for heart failure and kidney protection, indicating a broad future market potential [1] - The company is also developing LH-1802 for acute myeloid leukemia, which is in clinical trial stages, and LH-1901 for chronic obstructive pulmonary disease, which has initiated phase I clinical trials [1] Group 2: Collaborations and Achievements - The company collaborates with renowned research institutions and universities, including the Shanghai Institute of Pharmaceutical Industry, China Pharmaceutical University, and Zhejiang University, through its academician and doctoral workstations [1] - As of 2025, the company has obtained 13 production approvals and 2 clinical approvals, being one of the two companies to pass the consistency evaluation for methanesulfonic acid phenylephrine injection (1ml: 10mg) [1] - The company is one of three manufacturers in China for the market of benazepril potassium tablets and the first nationwide company to pass the consistency evaluation for hydrochloride quetiapine tablets [1]

Core Viewpoint - Fosen Pharmaceutical (01652) shares rose over 7% following the approval of its hypertension treatment, "Mei Asha Tan Potassium Tablets," by the National Medical Products Administration of China [1] Company Summary - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., developed "Mei Asha Tan Potassium Tablets," which have received regulatory approval for the treatment of primary hypertension [1] - The active ingredient, Mei Asha Tan Potassium, is an angiotensin II receptor antagonist that converts rapidly to the active component Azilsartan upon oral absorption, effectively lowering blood pressure by blocking the angiotensin II hormone [1] Industry Summary - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 100 billion RMB in 2022 [1] - "Sartan" medications play a crucial role within the family of antihypertensive drugs, indicating strong market demand and potential for growth in this segment [1]

Core Viewpoint - Fosen Pharmaceutical (01652) shares rose over 7% following the approval of its hypertension treatment, "Mei Asha Tan Potassium Tablets," by the National Medical Products Administration of China [1] Company Summary - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., received approval for "Mei Asha Tan Potassium Tablets," which are indicated for the treatment of primary hypertension [1] - The active ingredient, Mei Asha Tan Potassium, is an angiotensin II receptor antagonist that converts rapidly to the active component Azilsartan upon oral absorption, effectively lowering blood pressure by blocking the angiotensin II hormone [1] Industry Summary - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 100 billion RMB in 2022 [1] - "Sartan" drugs play a crucial role within the family of antihypertensive medications, indicating strong market demand and potential for growth in this segment [1]

Core Insights - The company has received approval from the National Medical Products Administration of China for its product "Mebsartan Potassium Tablets" (trademark: Kuanopeng), which is indicated for the treatment of primary hypertension [1][2] - "Mebsartan Potassium" is a significant addition to the company's product pipeline in the cardiovascular system sector, providing more treatment options for adult patients with primary hypertension [2] Group 1: Product Details - "Mebsartan Potassium" is an angiotensin II receptor antagonist that converts rapidly to its active form, Azilsartan, after oral administration, effectively lowering blood pressure by blocking angiotensin II hormone [1] - The product is classified as a Category B drug by the National Medical Insurance Administration, with no restrictions on insurance indications or disease types, making it a first-line antihypertensive medication for adults [1] Group 2: Market Context - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 10 billion RMB in 2022, highlighting its importance in the hypertension drug family [1] - The company’s "Mebsartan Potassium Tablets" are available in 40mg and 80mg dosages, catering to both mild to moderate and severe hypertension patients [2]